Drug Profile
Cefepime/tazobactam - Wockhardt
Alternative Names: FEP-TAZ; WCK 4282Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Wockhardt
- Class 2 ring heterocyclic compounds; Antibacterials; Azabicyclo compounds; Carboxylic acids; Cephalosporins; Small molecules; Sulfones; Triazoles
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Urinary tract infections
- No development reported Gram-negative infections
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Gram-negative-infections in USA (IV, Infusion)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in USA (IV, Infusion)
- 18 Oct 2019 Wockhardt completes the phase III trial in Urinary tract infections (Complicated) in Czech republic (IV) (EudraCT2017-005117-31)